^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD40 (CD40 Molecule)

    i
    Other names: CD40, CD40 Molecule, Bp50, Tumor Necrosis Factor Receptor Superfamily Member 5, CD40 Molecule, TNF Receptor Superfamily Member 5, CD40L Receptor, TNFRSF5, P50, Tumor Necrosis Factor Receptor Superfamily, Member 5, B Cell Surface Antigen CD40, B-Cell Surface Antigen CD40, B Cell-Associated Molecule, CD40 Antigen, CDW40, CDw40
    2d
    Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. (PubMed, Br J Cancer)
    Combination of SL172154 with MIRV did not improve upon the previously reported ORR for MIRV, while the combination with PLD resulted in a higher ORR than reported for PLD, albeit in a small number of patients. Limited tumor penetration of SL-172154, lack of durable CD47 blockade, inability to overcome T cell exhaustion and other mechanisms of resistance may explain these findings. Trial register number: NCT05483933.
    P1 data • Journal • Platinum resistant
    |
    FOLR1 ( Folate receptor alpha ) • CD40 (CD40 Molecule)
    |
    pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
    3d
    Phenotypically and functionally unique CD86 expression CD8 T cell subset shapes immune regulation in the tumor microenvironment. (PubMed, J Adv Res)
    CD86high CD8+ T cells constitute a distinct immunoregulatory subset in cancer. Their differentiation is driven by an IL-12-IRF5 program, and their crosstalk with DCs via CD86/CTLA-4 engagement promotes tolerogenic remodeling of the TME. Targeting CD86 on CD8+ T cells may disrupt this suppressive circuit and potentiate antitumor immunity.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • GZMB (Granzyme B) • CD40 (CD40 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • IRF5 (Interferon Regulatory Factor 5)
    5d
    Meta-Analysis of Genetic Variants Associated With HBV Infection Susceptibility and Hepatocellular Carcinoma Risk. (PubMed, J Viral Hepat)
    Based on these results, our meta-analysis brings together many studies to give a clearer picture of the genetic factors that influence HBV infection and HCC in different etiologic pathways. We found that immune-related genes and HLA class II variants seem to have roles in HBV persistence, while metabolic gene variants are major contributors to HCC risk.
    Clinical • Retrospective data • Journal
    |
    HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • CD40 (CD40 Molecule)
    6d
    IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. (PubMed, Sci Rep)
    The efficacy of the CD40 agonist was partially dependent on CD8⁺ T cells. Our findings underscore the complex role of IL-1 signaling in modulating immune responses in PDAC and caution against pursuing IL-1R1 blockade, either as monotherapy or combined with agonistic CD40 antibodies, in clinical trials for PDAC.
    Journal
    |
    CD8 (cluster of differentiation 8) • ITGAM (Integrin, alpha M) • CD40 (CD40 Molecule)
    9d
    CD83 as a novel prognostic biomarker for diffuse large B-cell lymphoma arising in immune deficiency/dysregulation among rheumatoid arthritis patients treated with methotrexate. (PubMed, J Clin Exp Hematop)
    Multivariate analysis identified CD83 IHC high expression as an independent predictor of non-SR cases. High CD83 expression is an independent prognostic factor in MTX-associated IDD-DLBCL, and combined evaluation may refine risk stratification and guide clinical decisions.
    Journal • IO biomarker
    |
    BCL6 (B-cell CLL/lymphoma 6) • PAX5 (Paired Box 5) • CD79A (CD79a Molecule) • ICOSLG (Inducible T Cell Costimulator Ligand) • CD40 (CD40 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • IL1R1 (Interleukin 1 receptor, type I) • TNFRSF13C (TNF Receptor Superfamily Member 13C)
    |
    nCounter® PanCancer Immune Profiling Panel
    |
    methotrexate
    10d
    New Schiff Base Derivative Triazines: Their Synthesis, Molecular Docking Studies, and Anticancer Activities in Human Lung Cancer Cells. (PubMed, Chem Biol Drug Des)
    The drug-likeness potential of the TrzSchf derivatives was evaluated based on Lipinski's Rule of Five parameters. Overall, both experimental and computational results suggest that TrzSchf 1-3 are promising lead candidates for further investigation in lung cancer therapy.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CHEK1 (Checkpoint kinase 1) • CASP3 (Caspase 3) • CD40 (CD40 Molecule)
    14d
    NF-κB pathway gene expression is elevated in the midbrain of people with high-inflammation schizophrenia. (PubMed, Brain Behav Immun)
    Together, these findings support that increased NF-κB induces cytokine mRNA expression in schizophrenia midbrain via multiple upstream activators and cell types. The widespread increase in multiple NF-κB transcripts highlights both redundant activation mechanisms and a putative attempt to control NF-κB activation.
    Journal • IO biomarker
    |
    TNFRSF1A (TNF Receptor Superfamily Member 1A) • TLR4 (Toll Like Receptor 4) • CD40 (CD40 Molecule) • IL1R1 (Interleukin 1 receptor, type I) • NFKBIA (NFKB Inhibitor Alpha 2)
    15d
    A CRISPR-Cas9 screen Reveals STEEP1 as a Key Host Dependency Factor for Epstein-Barr Virus Latent Membrane Protein 1 Trafficking and Signaling. (PubMed, bioRxiv)
    This analysis identified an ER-resident protein called STEEP1, previously implicated in support of trafficking of the DNA sensor STING, as a key LMP1 partner.We found that STEEP1 associates with LMP1 and supports LMP1 trafficking out of the endoplasmic reticulum to cellular signaling sites. As STEEP1 knockout impaired LMP1 function and LCL survival, our study identifies the STEEP1/LMP1 complex as a therapeutic target.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CD40 (CD40 Molecule)
    16d
    Elevation of Liver Elastic Value Following Radiofrequency Ablation Reflected Neutrophils Mediated Abscopal Effect in Liver Cancer. (PubMed, JHEP Rep)
    We linked clinical features to neutrophil-mediated immunity post-RFA. Neutrophil-activating therapy like CD40 agonists may prevent HCC relapse after RFA.
    Journal • IO biomarker
    |
    CD40 (CD40 Molecule)
    22d
    Smart nano-assembly from traditional Chinese medicine: manganese-enhanced polysaccharide platform for orchestrated cancer chemo-immunotherapy. (PubMed, J Adv Res)
    The LUT@POP-FH-Mn synergistically combines natural compounds and metal ions, improving drug delivery and efficacy through integrated chemotherapy, CDT, and immunotherapy. This work provides an innovative model for modernizing traditional Chinese medicine and demonstrates the promise of natural product-based nanomedicine for combined cancer therapy.
    Journal
    |
    CD40 (CD40 Molecule) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    22d
    Gene Network Enrichment Analysis and Its Application to Explore Enriched Immune Disease Pathways for Gene Network of Acute Myeloid Leukemia Cell Lines. (PubMed, J Comput Biol)
    Our results suggested that "activation of CD40 and CD40LG" and "mutual activation between HLA-DPB1 and IL4R" are potential markers to uncover AML-related mechanisms. Overall, this study demonstrates that GNEA provides a powerful framework for uncovering biologically meaningful interaction-level insights into complex diseases.
    Preclinical • Journal • IO biomarker
    |
    HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • CD40 (CD40 Molecule) • CD40LG (CD40 ligand)
    26d
    Focused Ultrasound Thermal Ablation and CD40 Agonism Reprograms Breast Tumor Immunity to Drive Regression and Memory. (PubMed, bioRxiv)
    Together, these findings establish T-FUS as an immune-potentiating partner for CD40 agonism, capable of driving durable, robust BC regression and immunological memory. This work positions T-FUS+CD40 agonism as a clinically scalable, in situ vaccination-like strategy with potential to benefit breast cancers, including luminal subtypes, that remain largely refractory to immune checkpoint blockade.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD40 (CD40 Molecule)